Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | PER2 | O15055 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562480 | 0.86 | APEX1 (0.38) | APEX1BLMBRD4PER2TP53 | |
| SCHEMBL562931 | 0.86 | APEX1 (0.38) | APEX1BLMBRD4PER2TP53 | |
| SCHEMBL8364228 | 0.79 | APEX1 (0.42) | APEX1BLMBRD4PER2TP53 | |
| SCHEMBL8365831 | 0.79 | FAAH (0.39) | BRD4L3MBTL1 | |
| SCHEMBL563087 | 0.75 | GSK3A (0.41) | APEX1BLMBRD4 | |
| SCHEMBL563088 | 0.75 | GSK3A (0.41) | APEX1BLMBRD4 | |
| SCHEMBL563180 | 0.74 | ALDH1A1 (0.45) | TP53L3MBTL1 | |
| SCHEMBL2034969 | 0.73 | PER2 (0.37) | APEX1BLMBRD4PER2POLB | |
| SCHEMBL7744060 | 0.73 | PER2 (0.37) | APEX1BLMBRD4PER2POLB | |
| SCHEMBL8364335 | 0.68 | PER2 (0.34) | APEX1BLMBRD4PER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420818-B2 | Process for the preparation of pyrido[2,1-a] isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120035368-A1 | PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES | ABRECHT STEFAN (CH) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035368-A1 | PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES | DPP4, DPP7, DPP3 | APEX1 1510/4885BLM 917/4885BRD4 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.